Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.81
-0.24-2.98%
At close: -
$7.67
-0.14-1.81%
After Hours: 5:01 PM EDT
Comments
Loading...
Aurinia Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AUPH | Benzinga
Aurinia Pharmaceuticals Inc has a consensus price target of $10.75 based on the ratings of 5 analysts. The high is $13 issued by HC Wainwright & Co. on September 6, 2024. The low is $8 issued by RBC Capital on February 16, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Cantor Fitzgerald, and HC Wainwright & Co. on September 16, 2024, September 9, 2024, and September 6, 2024, respectively. With an average price target of $11 between Cantor Fitzgerald, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 43.44% upside for Aurinia Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
RBC Capital
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Aurinia Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 09/16/2024 | Buy Now | 30.4% | Cantor Fitzgerald | Olivia Brayer16% | $10 → $10 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 30.4% | Cantor Fitzgerald | Olivia Brayer16% | $10 → $10 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 69.52% | HC Wainwright & Co. | Ed Arce56% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 69.52% | HC Wainwright & Co. | Ed Arce56% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 30.4% | Cantor Fitzgerald | Olivia Brayer16% | $12 → $10 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | 69.52% | HC Wainwright & Co. | Ed Arce56% | $15 → $13 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 4.32% | RBC Capital | Douglas Miehm48% | $13 → $8 | Maintains | Outperform | Get Alert |
| 09/22/2023 | Buy Now | 95.61% | HC Wainwright & Co. | Ed Arce56% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 95.61% | HC Wainwright & Co. | Ed Arce56% | $14 → $15 | Maintains | Buy | Get Alert |
| 07/06/2023 | Buy Now | 95.61% | Cantor Fitzgerald | Olivia Brayer16% | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2023 | Buy Now | 82.57% | HC Wainwright & Co. | Ed Arce56% | → $14 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 43.44% | RBC Capital | Douglas Miehm48% | → $11 | Reiterates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | 43.44% | RBC Capital | Douglas Miehm48% | $10 → $11 | Maintains | Outperform | Get Alert |
| 11/07/2022 | Buy Now | 82.57% | HC Wainwright & Co. | Ed Arce56% | $26 → $14 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 30.4% | RBC Capital | Douglas Miehm48% | $18 → $10 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | — | Oppenheimer | Justin Kim37% | — | Downgrade | Outperform → Perform | Get Alert |
| 11/04/2022 | Buy Now | 56.48% | SVB Leerink | Joseph Schwartz65% | $17 → $12 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 239.05% | HC Wainwright & Co. | Ed Arce56% | $30 → $26 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | 69.52% | Oppenheimer | Justin Kim37% | $15 → $13 | Maintains | Outperform | Get Alert |
| 05/05/2022 | Buy Now | 226.01% | Cantor Fitzgerald | Olivia Brayer16% | → $25 | Assumes | → Overweight | Get Alert |
| 05/05/2022 | Buy Now | 291.21% | HC Wainwright & Co. | Ed Arce56% | $33 → $30 | Maintains | Buy | Get Alert |
| 04/28/2022 | Buy Now | 186.89% | RBC Capital | Douglas Miehm48% | $27 → $22 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Aurinia Pharmaceuticals (AUPH) stock?
The latest price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $10.00 expecting AUPH to rise to within 12 months (a possible 30.40% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aurinia Pharmaceuticals (AUPH)?
The latest analyst rating for Aurinia Pharmaceuticals (NASDAQ:AUPH) was provided by Cantor Fitzgerald, and Aurinia Pharmaceuticals reiterated their overweight rating.
When was the last upgrade for Aurinia Pharmaceuticals (AUPH)?
There is no last upgrade for Aurinia Pharmaceuticals
When was the last downgrade for Aurinia Pharmaceuticals (AUPH)?
The last downgrade for Aurinia Pharmaceuticals Inc happened on November 4, 2022 when Oppenheimer changed their price target from N/A to N/A for Aurinia Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Aurinia Pharmaceuticals (AUPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aurinia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aurinia Pharmaceuticals was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.
Is the Analyst Rating Aurinia Pharmaceuticals (AUPH) correct?
While ratings are subjective and will change, the latest Aurinia Pharmaceuticals (AUPH) rating was a reiterated with a price target of $10.00 to $10.00. The current price Aurinia Pharmaceuticals (AUPH) is trading at is $7.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.